Heart failure, diabetes, and a kidney-protective drug
A new analysis published in *Diabetes Care* investigates the complex relationship between heart failure events, the onset of new diabetes, and the effects of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is a drug with established benefits for slowing chronic kidney disease progression and reducing cardiovascular events in patients with type 2 diabetes. This research delves into how intervening with finerenone might influence the interplay between worsening heart failure and the development of new-onset diabetes, a critical comorbidity that significantly elevates the risk of further cardiovascular and renal complications.
Why it might matter to you: For nephrology professionals, this study underscores the interconnected pathophysiology of cardiorenal metabolic syndromes. The findings highlight a potential therapeutic strategy targeting the renin–angiotensin–aldosterone system (RAAS) that may concurrently mitigate heart failure progression and diabetic nephropathy risk. Understanding these interactions is crucial for managing patients with overlapping chronic kidney disease, cardiovascular disease, and metabolic disorders, informing more integrated treatment approaches.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.